Filing Flows › Comparisons › PULM vs LYEL
Pulmatrix vs Lyell Immunopharma: PULM and LYEL compared
Pulmatrix is the larger company: $3K of revenue in its latest quarter (Q4 2024) against $3K for Lyell Immunopharma (Q3 2026). Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
Where the money goes: PULM and LYEL
Pulmatrix (PULM) · Q4 2024
Pulmatrix, Q4 2024: revenue $3K (-100% year over year), net loss $2.0M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Pulmatrix (PULM) | Lyell Immunopharma (LYEL) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q3 2026 |
| Revenue | $3K | $3K |
| Revenue growth, Y/Y | -100% | -80% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.0M | −$45.5M |
| Operating cash flow | −$1.3M | −$34.6M |
Questions
Which is bigger, Pulmatrix or Lyell Immunopharma?
Pulmatrix is the larger company: $3K of revenue in its latest quarter (Q4 2024) against $3K for Lyell Immunopharma (Q3 2026).
Is Pulmatrix or Lyell Immunopharma growing faster?
Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
More: Pulmatrix earnings · how Pulmatrix makes money · Lyell Immunopharma earnings · how Lyell Immunopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 21, 2025; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.